



AngioDynamics Announces a Partnerships in Clinical Trial Engagements (PCTE) Initiative

AngioDynamics introduces a new grant opportunity that encourages clinical trial sites to build partnerships within underserved communities to increase patient participation.

AngioDynamics, Inc., a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life, announced its Partnerships in Clinical Trial Engagements (PCTE) initiative. The PCTE initiative aims to increase patient involvement in clinical trials in underrepresented communities by offering grants to healthcare providers. These grants will further develop relationships or programs that aim to advance healthcare by producing more inclusive clinical trial data. AngioDynamics is committed to educating key constituencies about the current clinical study landscape and addressing disparities in healthcare through this PCTE initiative. The PCTE initiative emphasizes building mutually beneficial relationships between healthcare providers and underrepresented patient populations. Through this collaboration, solutions will be developed to advance health equity. "We believe every patient deserves access to quality care, and clinical trials should reflect the diversity of society," said Juan Carlos Serna, Sr. VP, Scientific & Clinical Affairs. "Our PCTE initiative is our commitment to ensuring everyone has an equal chance to participate in important studies."

AngioDynamics is currently enrolling patients in three separate US IDE clinical studies. The **PRESERVE** study for the treatment of patients with prostate cancer with the NanoKnife System, the **APEX-AV** study for the treatment of patients with pulmonary embolism with the AlphaVac MMA F18⁸⁵ System, and the **DIRECT** study for the treatment of patients with pancreatic cancer with the NanoKnife System.

To learn more about the Partnerships in Clinical Trial Engagements initiative, reach out to the clinical affairs team here: clinicalaffairs@angiodynamics.com

About the NanoKnife System

The NanoKnife System utilizes Irreversible Electroporation (IRE) technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue. Visit nanoknife.com for full product information. Visit bit.ly/NanoKnifeRiskInfo for risk information. The NanoKnife System has been cleared by the FDA for the surgical ablation of soft tissue. It has not received clearance for the therapy or treatment of any specific disease or condition.

About the AlphaVac MMA F18⁸⁵ System

The AlphaVac MMA F18⁸⁵ System is an emergent first-line device that is currently cleared for the removal of thromboemboli from the venous system. The System includes an ergonomic handle, an 18F cannula with an 85-degree angle, an obturator, and a waste bag assembly. The APEX-AV Study was designed to provide safety and efficacy data for a clearance specific to PE. Visit <https://bit.ly/Angio-risk-info> for risk information.

The AlphaVac MMA F18⁸⁵ System when used for the treatment of pulmonary embolism is an investigational device. Limited by United States law to investigational use.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients.

The Company's innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

AngioDynamics, NanoKnife, and AlphaVac are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary.